Leppert John T, Shvarts Oleg, Kawaoka Kelly, Lieberman Ron, Belldegrun Arie S, Pantuck Allan J
Department of Urology, David Geffen School of Medicine at UCLA, CA 90095-1738, USA.
Eur Urol. 2006 Feb;49(2):226-34. doi: 10.1016/j.eururo.2005.12.011. Epub 2005 Dec 28.
Bladder cancer represents an ideal tumor model to test and apply cancer prevention strategies. In addition to reviewing the epidemiology of transitional cell carcinoma (TCC), we review the current status and the future directions of bladder cancer prevention.
A literature review of peer-reviewed articles which address bladder cancer prevention was performed.
Pre-clinical and limited clinical data suggest that bladder cancer is responsive to efforts to delay or prevent its development in at-risk patients, and in reducing the risk of recurrence in patients with established disease. Many epidemiologic studies, however, investigating natural products, such as vitamins and herbal compounds, lack conclusive evidence of their chemopreventive effects.
While many agents hold promise in the prevention of bladder cancer, none currently can be recommended as proven chemoprevention strategies. Improving the accuracy of patient risk assessment and identification of surrogate endpoint biomarkers are crucial to the testing of these strategies. Efficient study design will ensure rapid and substantial advances in the chemoprevention of bladder cancer.
膀胱癌是测试和应用癌症预防策略的理想肿瘤模型。除了回顾移行细胞癌(TCC)的流行病学外,我们还将回顾膀胱癌预防的现状和未来方向。
对已发表的关于膀胱癌预防的同行评审文章进行了文献综述。
临床前和有限的临床数据表明,膀胱癌对于延迟或预防高危患者发病以及降低已确诊疾病患者的复发风险方面是有反应的。然而,许多调查天然产物(如维生素和草药化合物)的流行病学研究缺乏其化学预防作用的确凿证据。
虽然许多药物在预防膀胱癌方面具有前景,但目前尚无一种可被推荐为经证实的化学预防策略。提高患者风险评估的准确性和识别替代终点生物标志物对于这些策略的测试至关重要。高效的研究设计将确保膀胱癌化学预防方面能迅速取得重大进展。